NCT05444062Active, not recruiting
Quebec Lung Cancer Screening PLUS Trial
Quebec Lung Cancer Screening PLUS Trial - a Randomized Controlled Trial of an Educational Intervention for Untreated Chronic Obstructive Pulmonary Disease (COPD) and/or Cardiovascular Disease (CVD) Identified During Lung Cancer Screening
Source: ClinicalTrials.gov · Last updated 11 Aug 2025
Brief summary (registry, in English)
Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- First submitted
- 27 Jun 2022
- Start date
- 23 Apr 2023
- Primary completion date
- Feb 2026
- Lead sponsor
- Nicole Ezer, MD, FRCPC, MPH
- Diseases
- COPD, Lung cancer
- NCT number
- NCT05444062
What you commit to
- Study type: Interventional
- Planned participants: 330
- From 23 Apr 2023 to the primary completion date, Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- COPD aim: asymptomatic, or already on appropriate first line COPD therapy.
Other illness
- Any participant with a high suspicion of lung cancer, defined as Lung-RADS (Lung Imaging Reporting and Data System) 3 or 4, as this is an inopportune time to initiate new medical therapies.
- Cardiovascular aim: Absent CAC, known clinical atherosclerosis, known former heart surgery, Diabetes Mellitus.
Who the study is looking for
- Patient screened for lung cancer as part of the Quebec Lung Cancer Demonstration project by low dose CT scan of the chest.
- Cardiovascular aim: mild to severe CAC identified on low dose CT, not on guideline recommended lipid-lowering therapy.
- COPD aim: diagnosed with COPD, symptomatic (mMRC \>=1 or CAT\>= 10) and untreated, or not on first line guideline recommended therapy for COPD.
Age in the registry: 55 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Health Center Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.